PercuSense Announces Project with the University of Melbourne funded by The Helmsley Charitable Trust to Develop a Single Sensor Continuous Glucose and Ketone Monitor
November 2, 2020
By combining glucose and ketone on a single implantable sensor, PercuSense aims to reduce the risk of diabetic ketoacidosis, reducing the burden and ultimately increasing the treatment options for people with diabetes.
PercuSense Awarded $4.6M DIU/DTRA Contract to Develop Continuous Biosensor System for Early Detection of Toxic Chemical Exposure
May 28, 2020
PercuSense will leverage its continuous monitoring platform to create a field deployable on-body system designed to rapidly identifying chemical exposure and providing real time alerts to warfighters to drive threat reduction measures and treatment interventions.
Integration of Ketone Sensing into Closed Loop Systems: The Clinical Case
January 12, 2019
PercuSense’s founder, Rajiv Shah, contributed to a paper highlighting the clinical need and technical possibilities for combining a ketone sensor and glucose sensor into a single device. Such a device would provide the safety net that can prevent potentially serious incidents of diabetic ketoacidosis.
PercuSense Announced as a Finalist for MedTech Innovator Execution Award
September 18, 2018
PercuSense was named one of five finalists for the Execution Award, recognizing the potential of a promising entrepreneurial medical technology company.
PercuSense Selected to Participate in Medtech Innovator Startup Accelerator
June 13, 2018
PercuSense is honored to be selected as one of 25 early-stage companies participating in the Medtech Innovator Accelerator program. This sought-after program pairs companies with healthcare industry leaders who provide support and mentorship.